An alternative joint industry effort will provide information on combination versus single agent therapy for treatment of aspergillosis

To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.

Inclusion Criteria:

• Proven, probable or possible invasive aspergillosis
• Patient is 2 years of age or older

Exclusion Criteria:

• The patient has been administered an antifungal agent (voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B, or lipid formulation of amphotericin B) for >7 days immediately prior to randomization for treatment of the Possible, Probable, or Proven invasive aspergillosis for which the patient is being enrolled.
• The patient has been treated with voriconazole for > 7 days immediately prior to randomization